(Reuters) -Biomea Fusion’s experimental drug showed sustained blood sugar control in patients with type 2 diabetes and may benefit those not responding to GLP-1 therapies like Novo Nordisk’s Ozempic, it said on Monday.

Blood sugar levels stayed lower nine months after discontinuing treatment with the drug, icovamenib, suggesting it might help restore the cells that produce insulin.

In the year-long mid-stage study, patients with type 2 diabetes who weren’t seeing results from Novo’s Ozempic also showed noticeable improvement after 12 weeks of treatment, Biomea said.

Icovamenib reduced blood sugar levels in such patients by an average of 1.3%, compared with those on placebo. The reduction in the overall study population was 1.8%.

Icovamenib works by partially blocking a protein called m

See Full Page